Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | VEGFA | P15692 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18700880 | 1.00 | FAAH (0.53) | FAAHOPRD1OPRL1VEGFAEGLN1 | |
| SCHEMBL3566467 | 0.86 | ALDH1A1 (0.54) | FAAHSPHK2SPHK1HDAC8HDAC6 | |
| SCHEMBL13343697 | 0.86 | HDAC8 (0.51) | FAAHSPHK2SPHK1HDAC8HDAC6 | |
| SCHEMBL3563591 | 0.86 | HDAC8 (0.51) | FAAHSPHK2SPHK1HDAC8HDAC6 | |
| SCHEMBL13343700 | 0.86 | ALDH1A1 (0.54) | FAAHSPHK2SPHK1HDAC8HDAC6 | |
| SCHEMBL18801723 | 0.85 | VEGFA (0.63) | FAAHVEGFAEGLN1SPHK2SPHK1 | |
| SCHEMBL791665 | 0.85 | VEGFA (0.63) | FAAHVEGFAEGLN1SPHK2SPHK1 | |
| SCHEMBL14395220 | 0.83 | MAPK1 (0.54) | FAAHOPRD1SPHK2SPHK1 | |
| SCHEMBL11990426 | 0.83 | MAPK1 (0.54) | FAAHOPRD1SPHK2SPHK1 | |
| SCHEMBL14779735 | 0.82 | FAAH (0.50) | FAAHOPRL1VEGFAEGLN1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351530-B2 | Arylcyclohexyl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-16 | — | — | US | disclosed |
| US-10351530-B2 | Arylcyclohexyl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-16 | — | — | US | disclosed |
| US-20180282283-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| EP-3371167-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017060855-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060855-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282283-A1 | ARYLCYCLOHEXYL PYRAZOLES AS NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | FAAH 3300/4885OPRD1 886/4885OPRL1 1918/4885 |
| US-10351530-B2 | Arylcyclohexyl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | FAAH 3300/4885OPRD1 886/4885OPRL1 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.